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Abstract: One purpose of clinical neurochemistry has 
been to indicate “ activities'’ of catecholamine systems, 
by assaying levels of the effector compounds or their 
metabolites in body fluids such as plasma, cerebrospinal 
fluid, urine, or microdialysate. This review discusses a 
new purpose: relating specific catecholaminergic pheno­
types to neurogenetic disorders. Distinctive catechol­
amine patterns in several neurogenetic conditions reflect 
enzyme deficiencies as direct or indirect effects of gene 
mutations. These neurochemical patterns can provide 
potentially important clues to the diagnosis, treatment, 
and pathophysiology of neurogenetic disorders. Linking 
genetic abnormalities with molecular mechanisms and 
clinical manifestations of disease represents a useful new 
direction in clinical neurochemistry. Key Words: Neuro­
chemistry— Catecholamines— Norepinephrine— Do­
pamine— DOPA— Phenotype— Neurogenetics.
J. Neurochem. 67, 1781-1790 (1996).
Until recently, clinical catecholamine neurochemis­
try has been used mainly to examine release of cate­
cholamines as effector chemicals in the brain and pe­
riphery, in order to indicate “ activities5’ of central or 
peripheral neuronal systems. The development of assay 
techniques for simultaneous measurements of concen­
trations of catecholamines, the catecholamine precur­
sor DOPA, and catecholamine metabolites, such as 
dihydroxyphenylglycol (DHPG), dihydroxyphenyl- 
acetic acid (DOPAC), methoxyhydroxyphenylglycol 
(MHPG), homo vanillic acid (HVA), metanephrine 
(MN), and normetanephrine (NMN), has enabled de­
tailed and comprehensive assessments of specific as­
pects of catecholaminergic function, including release, 
neuronal and extraneuronal uptake and metabolism, 
turnover, and synthesis (Eisenhofer et al, 1992).
The availability of these simultaneous assays has 
led to a novel application of clinical catecholamine 
neurochemistry: the delineation of neurochemical pat­
terns associated with specific genetic abnormalities.
These patterns can provide potentially important clues 
to the diagnosis, treatment, and pathophysiology of 
neurogenetic disorders. This brief review summarizes 
what has been learned so far from this new approach.
Understanding the clinical significance of catechol­
amine phenotypic changes requires detailed knowledge 
about the sources and meanings of levels of DOPA, 
catecholamines, and catecholamine metabolites in hu­
man physiological fluids, such as plasma (Figs. 1 and
2, Table 1), and knowledge about the chromosomal 
sites of genes encoding proteins participating in the 
synthesis, storage, release, metabolism, and recycling 
of catecholamines (Table 2).
GENETIC DISEASES WITH SPECIFIC 
CATECHOLAMINERGIC PHENOTYPES: 
SYNTHESIS
In mammals, catecholamine biosynthesis stems 
from a single enzymatic step— conversion of the 
amino acid tyrosine to the catechol amino acid l- 
DOPA by tyrosine hydroxylase (TH; EC 1.14.13.41; 
Fig. 1). Circulating catecholamines seem crucial for 
normal neurodevelopment, because genetic disorders 
of catecholamine biosynthesis typically produce severe 
neurological defects or fetal wastage. Thus, of mice 
with knockout of the TH gene, ~90% die in utero 
(Zhou et al., 1995).
Address correspondence and reprint requests to Dr. D. S. 
Goldstein at NINDS, NIH, 10/6N252, 10 Center Drive, MSC-1424, 
Bethesda, MD 20892-1424, U.S.A.
Abbreviations used: AD, aldehyde dehydrogenase; AR, aldehyde 
reductase (alcohol dehydrogenase, EC 1.1.1.1); BH4, tetrahydrobio- 
pterin; COMT, catechoi-Omethyltransferase; DA, dopamine; DBH, 
dopamine-/?-hydroxylase; DHPG, dihydroxyphenylglycol; DHPR, 
dihydropteridine reductase; DOPAC, dihydroxyphenylacetic acid; 
EPI, epinephrine; HVA, homovanillic acid; LAAAD, L-aromatic 
amino acid decarboxylase; MAO, monoamine oxidase; MHPG, me­
thoxyhydroxyphenylglycol; MN, metanephrine; NE, norepinephrine; 
NMN, normetanephrine; PNMT, phenylethanolamine-N-meihyl- 
transferase; PST, phenolsulfotransferase; TH, tyrosine hydroxylase; 
VAT, vesicular amine transporter; VMA, vanillylmandelic acid.
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Compound
l-DOPA
DA
NE
EPI
DOPAC
DHPG
NMN
MN
MHPG
VMA
HVA
TABLE 1, Sources and physiological meanings of concentrations of l-DOPA, catecholamines,
and catecholamine metabolites
Source
Sympathetic nerves and unknown
Sympathetic nerves and unknown
Sympathetic nerves and (to a much smaller 
extent) adrenal medulla
Adrenal medulla
Enzymatic actions of MAO and AD on DA
Enzymatic actions of MAO-A and AR on 
axoplasmie NE
Enzymatic actions of COMT on NK
Enzymatic actions of COMT on adrenomedullary 
EP1 mainly before enlry of EPI into the 
circulation
Enzymatic actions of COMT on DHPG and of 
COMT and MAO on NE
Enzymatic actions of AD on MHPG in liver
Enzymatic actions of COMT on DOPAC
DA sulfate Conjugation of DA, mainly in gut
Meaning
Alterations may reflect changes in TH activity and catecholamine 
biosynthesis
Alterations may reflect large increases in exocytotic release
Alterations indirectly reflect exocytotic release, modulated by reuptake 
and presynaptic adrenoceptors
Index of adrenomedullary secretion
Reflects MAO and AD activities, indirectly reflects TH, DBH, vesicular 
and transmembrane transporters, and extraneuronal COMT activity
Reflects MAO-A and AR activities, indirectly reflects DBH, vesicular 
and transmembrane transporters, extraneuronal COMT activity» and 
vesicular NE stores
Reflects extraneuronal uptake and COMT activity in nonneuronal cells
Reflects extraneuronal uptake and COMT activity in nonneuronal cells
Reflects extraneuronal uptake and COMT activity in nonneuronal cells
Reflects hepatic metabolism of circulating and locally generated MHPG 
Reflects extraneuronal uptake and COMT activity in nonneuronal cells 
Possibly reflects inactivation of autocrine/paracrine DA
For abbreviations, see legend to Fig. I.
Tyrosine hydroxylation requires tetrahydrobiopterin 
(BH4) as a cofactor. In humans, genetic deficiencies 
of BH4 synthesis or recycling, although compatible 
with survival to birth, obviate normal postnatal neuro­
logical development if not recognized and treated ap­
propriately from early infancy.
Dihydropteridine reductase (DHPR) deficiency
DHPR (EC 1.6.99.7) catalyzes the conversion of di- 
hydrobiopterin to BH4. BH4 is a required cofactor for 
hydroxylation not only of tyrosine but also of phenylala­
nine and tryptophan. BH4 also appears to play a role in 
maintaining the bioactive (tetrahydro) form of folic acid 
(Pollock and Kaufman, 1978). Because of impaired 
phenylalanine hydroxylation, patients with DHPR defi­
ciency have a variant of phenylketonuria. In contrast to 
classical phenylketonuria (caused by specific mutations 
in the phenylalanine hydroxylase gene), where dietary 
restriction of phenylalanine beginning in infancy pro­
tects against mental retardation, patients with DHPR 
deficiency develop seizures and serious neurodevelop- 
mental delays even with good dietary control of phenyl­
alanine intake (Kaufman et al., \915a,b).
These clinical problems presumably arise from de­
ficient activities of TH and tryptophan hydroxylase 
and from defective folate metabolism. Corresponding 
biochemical consequences include the following : low 
CSF levels of metabolites of dopamine (DA) and nor­
epinephrine (NE) (Fig. 1), such as DOPAC, HVA, 
DHPG, MHPG, and vanillylmandelic acid (VMA);
low CSF levels of the serotonin metabolite 5-hydroxy- 
indoleacetic acid; and low CSF levels of tetrahydrofo- 
late (Niederwieser et al., 1985; Goldstein etal., 1995). 
Therapy combining phenylalanine restriction with oral 
administration of l-DOPA, 5-hydroxy tryptophan (pre­
cursor of serotonin), and folinic acid appears to im­
prove neurodevelopmenta 1 outcomes in DHPR-defi- 
cient patients (Irons et al., 1987; Goldstein et al., 1995; 
Smooker et aL, 1995).
At least 14 different mutations have been described 
at the DHPR locus (Matsubara et al,, 1992; Dianzani 
et al., 1993; Smooker et al., 1993, 1995) on chromo­
some 4 (Sumi et al., 1990). Combinations of neuro- 
cheinical assessments with mutation detection or func­
tional characterization of abnormal DHPR alleles 
should help elucidate relationships between genotype 
and clinical phenotype in DHPR deficiency. Moreover, 
in a patient we studied (Goldstein et al., 1995), the 
pretreatment neurochemical findings (low but detect- 
able plasma levels of DOPA and normal levels of NE, 
despite absent DHPR activity in erythrocytes and fi­
broblasts) led to the suggestion of a DHPR-indepen- 
dent mechanism for recycling BH4, illustrating how 
neurochemical analyses in patients with rare disorders 
can also enhance general understanding of catechol­
amine metabolism.
As suggested by the pathways in Fig. 2, defects in 
GTP-cyclohydrolase I (EC 3.5.4.16) or 6-pyruvoyl tet- 
rahydropterin synthase (no EC number listed) can also
J. Neurochem., Vol. 67, No. 5, 1996
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FIG. 1. Overview of catecholamine synthetic and metabolic pathways. Note single pathway of catecholamine synthesis, via hydroxyla- 
tion of tyrosine and decarboxylation of l-DOPA, compared with multiple pathways of catecholamine metabolism. Abbreviations used: 
5-CH3-H4-folate, 5-methyltetrahydrofolate; THF, tetrahydrofolate; q-BH2> quinonoid dihydrobiopterin; MTHFR, methyltetrahydrofolate 
reductase; DHPR, dthydropteridine reductase; BH4, tetrahydrobiopterin; Tyr, tyrosine; TH, tyrosine hydroxylase; COMT, catechol-O- 
methyltransferase; PST, phenylsulfotransferase; 3-MTyrosine, 3-methoxytyrosine; LAAAD, L-aromatic amino acid decarboxylase; 
D0PA-S04, l-DOPA sulfate; DA, dopamine; DA-SO4 , dopamine sulfate; MAO, monoamine oxidase; AD, aldehyde dehydrogenase; AR, 
aldehyde reductase; DBH, dopamine**/?-hydroxy!ase; NE, norepinephrine; 3-MT, 3-methoxytyramine; 3-MT-S04j 3-methoxytyramine 
sulfate; PNMT, phenylethanolamine-A/-methyltransferase; NMN, normetanephrine; EPI, epinephrine; MN, metanephrine; DHPG, dihy- 
droxyphenylglycol; MHPG, methoxyhydroxyphenylglycol; EPI-S04, epinephrine sulfate; NMN-S04, normetanephrine sulfate; MN-S04, 
metanephrine sulfate; DHPG~S04, dihydroxyphenylglycol sulfate; MHPG-S04, methoxyhydroxyphenylglycol sulfate; VMA, vanillylman- 
delic acid; DOPAC, dlhydroxyphenylacetic acid; HVA, homovanillic acid.
produce atypical phenylketonuria due to defective BH4 
synthesis (Scrìver et al., 1996). Complete deficiency of 
either enzyme leads to about the same clinical syn­
drome, with seizures, limb hypertonia, intermittent hy­
perthermia (Scriver et al., 1996), and predictable asso­
ciated neurotransmitter abnormalities (Dhondt, 1984; 
Niederwieser et al., 1984). Heterozygosity for mutation 
at the GTP-cyclohydrolase I locus produces DOPA-re- 
sponsive dystonia, as discussed later.
Deficiency of sepiapterin reductase (EC 1.1.1.153)
or of carbinolamine dehydratase (no EC number 
listed), other enzymes in BH4 synthesis and recycling 
(Fig. 1) should also produce predictable clinical and 
neurochemical abnormalities. As carbinolamine dehy­
dratase catalyzes a reaction that can also occur nonen- 
zymatically, however, individuals with complete ab­
sence of this enzyme have mild clinical findings and 
only transient biochemical changes (Citron et al., 
1993). Examples of sepiapterin reductase deficiency 
have not been reported to date.
J. Neurochem., Vol. 67, No. 5, 1996
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FIG. 2. Pathways of de novo synthesis and recycling of BH4. Abbreviations are as in the legend to Fig. 1
Vitiligo
Progressive depigmentation in vitiligo reflects nei­
ther a neurological nor a clearly inherited condition. 
This disorder, nevertheless, merits inclusion in this re­
view, because vitiligo patients may have localized, cell 
type-specific abnormalities of catecholamine biosyn­
thesis (Schallreuter et aL, 1994). Affected individuals 
have three- to fivefold increases in epidermal GTP- 
cyclohydrolase I activity and decreased activity of car- 
binolamine dehydratase (Schallreuter et al., 1994). 
This combination increases formation of 7-BH4 (Fig. 
2 ), a by-product that potently inhibits phenylalanine 
hydroxylase (Adler et al, 1992; Davis et al., 1992). 
The genetic factors related to these alterations remain 
unknown.
Vitiligo patients have been reported to have in­
creased rates of urinary excretion of HVA and VMA, 
especially during the onset and in progressive active 
phases (Morrone et al., 1992). Increased urinary ex­
cretion of norepinephrine has been noted in some af­
fected individuals (Schallreuter et al., 1994). Data 
concerning plasma catecholamine levels have been in­
consistent (Orecchia et al., 1994; Schallreuter et al., 
1994), possibly due to a localized catecholaminergic 
abnormality. Additional genetic and neurochemical 
studies of patients with this disorder would be useful.
L-DOPA-responsive dystonia
L-DOPA-responsive dystonia, which is inherited as 
an autosomal dominant trait, includes childhood-onset
dystonia, abnormal gait, marked diurnal fluctuation 
(symptoms aggravated in the evening and alleviated 
in the morning after rest), concurrent or later develop­
ment of parkinsonism, and normal cognitive function. 
Oral l-DOPA treatment dramatically improves the 
neurologic symptoms.
It was the pattern of biochemical abnormalities in 
L-DOPA-responsive dystonia— low brain and CSF 
levels of DA, HVA, and BH4 (Nygaard, 1993; Nygaard 
et al., 1994; Rajput et al., 1994; Takahashi et al.,
1994) — that led initially to the prediction that the dis­
order would be found to arise from deficient DA syn­
thesis due to decreased tyrosine hydroxylation. Genetic 
linkage analysis localized the putative mutant gene to 
chromosome 14q (Nygaard et al., 1993), but no candi­
date genes emerged from the genetic maps, until Ichi- 
nose and co-workers mapped the human GTP-cyclohy- 
drolase gene to the L-DOPA-responsive dystonia criti­
cal region (Ichinose et ai., 1994). The same workers 
demonstrated GTP-cyclohydrolase mutations in L- 
DOPA-responsive dystonia patients and documented 
severely reduced enzyme activity in affected patients. 
Numerous other GTP-cyclohydrolase mutations have 
since been reported in L-DOPA-responsive dystonia 
patients (Hirano et al., 1995; Furukawa et al., 1996), 
including a splice junction defect that produces skip­
ping of exon 2 and predicts a truncated protein (Hirano 
et al., 1995). Thus, the neurochemical abnormalities 
in L-DOPA-responsive dystonia not only fit the genetic
J. Neitrochem., Vol. 67, No. 5, 1996
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abnormalities identified so far but also predicted the 
type of genetic defect.
Whether an individual possesses one or two mutant 
GTP-cyclohydrolase alleles profoundly influences the 
resultant neurological phenotype. Comparisons of neu­
rochemical phenotypes in patients with autosomal re­
cessive GTP-cyclohydrolase deficiency (atypical phen­
ylketonuria) or autosomal dominant GTP-cyclohydro­
lase deficiency (L-DOPA-responsive dystonia) would 
be informative and potentially could provide insights 
about treatment possibilities.
L-Aromatic amino acid decarboxylase (LAAAD) 
deficiency
LAAAD (EC 4.1.1.28) catalyzes the conversion of
l-DOPA to DA (Fig. 1) and of 5-hydroxytryptophan 
to serotonin. The enzyme requires pyridoxal-5'-phos­
phate (vitamin B6). A case report describing twins 
with profound deficiency of this enzyme (Hyland et 
al., 1992) noted that the probands, products of a con­
sanguineous (first cousin) marriage, appeared normal 
at birth but developed slowly, with hypotonia and ab­
normal eye and limb movements by 2 months of age. 
A similarly affected older sibling had died when 9 
months old. Both twins had low CSF and plasma levels 
of monoamines and high levels of DOPA and 5-hy­
droxytryptophan, from which the authors deduced the 
underlying enzymatic defect. As the parents each had 
intermediate LAAAD enzyme activity, the neurochem­
ical findings suggested heterozygosity for a mutant 
LAAAD allele. Treatment of the affected twins during 
infancy with pyridoxine, bromocriptine, and tranylcy­
promine produced some clinical benefit, although at 4 
years of age neurodevelopment remained subnormal 
(Hyland et al., 1993). Treatment commencing earlier 
in infancy might be more successful.
To our knowledge, the exact mutation in this, or any 
other, inherited form of LAAAD deficiency has not 
yet been defined. The human gene encoding LAAAD 
has been mapped to chromosome 7 (Craig et al., 1992; 
Scherer et al., 1992) and cloned. Two protein isoforms, 
resulting from alternative mRNA splicing, have been 
identified (O’Malley et al., 1995).
Dopamine-/?-hydroxylase (DBH) deficiency
Although mutant mice lacking DBH (EC 1,14.17.1) 
die during fetal development (Thomas et al., 1995), 
humans with absent DBH activity have surprisingly 
few neurological signs. Orthostatic hypotension invari­
ably occurs (Robertson et al., 1986), associated with 
extremely low or absent concentrations of NE, DHPG, 
VMA, and MHPG and increased concentrations of DA, 
DOPAC, HVA, and l-DOPA (Goldstein et al., 1989). 
The increase in plasma DOPA levels suggests compen- 
satorily increased tyrosine hydroxylation in sympa­
thetic nerves (Goldstein et al., 1987). Treatment with 
dihydroxyphenylserine, an amino acid converted to NE 
by decarboxylation, bypasses the enzymatic defect and 
produces remarkable clinical improvement in patients 
with DBH deficiency (Robertson et al., 1993). Treat­
ment with dihydroxyphenylserine also rescues DBH- 
deficient mice (Thomas et al., 1995).
As noted for LAAAD deficiency, no specific muta­
tions have been reported to date for patients with con­
genital absence of DBH. The lack of immunoreactive 
DBH in plasma or CSF (O ’Connor et al., 1994) sug­
gests that the underlying molecular defect may involve 
abnormal expression of the DBH gene, such as by a 
mutation affecting the DBH promoter, splice junctions, 
or coding sequence.
Menkes disease
Menkes disease is an X-linked recessive cause of 
infantile neurodegeneration that results from mutations 
in a gene encoding a copper-transporting ATPase 
(Chelly et al, 1993; Mercer et al., 1993; Vulpe et 
al., 1993; Das et al., 1994). Clinical features include 
seizures, severe developmental delay, failure to thrive, 
connective tissue abnormalities, such as bladder diver­
ticula and skin laxity, hair abnormalities ( ‘‘pili torti” ), 
and death in infancy or early childhood (Kaler, 1994). 
Other syndromes with less severe neurological pheno­
types (e.g., occipital horn syndrome) have also been 
associated with mutations at this locus (Kaler et al.,
1994). The clinical findings in Menkes disease and 
its variants result from reduced activities of copper- 
containing proteins, such as ceruloplasmin, cyto­
chrome c oxidase, superoxide dismutase, lysyl oxidase, 
and DBH. Because the patients have impaired intesti­
nal copper absorption, serum copper levels are low 
after the first 2 months of life.
Decreased DBH activity in patients with Menkes 
disease causes a distinctive, abnormal pattern of 
plasma and CSF catechols (Kaler et al., 19936), with 
high concentrations of DOPA, DOPAC, and DA, low 
concentrations of DHPG (an index of intraneuronal NE 
turnover), and approximately normal concentrations of 
NE itself, consistent with compensatory increases in 
sympathetic nerve traffic and tyrosine hydroxylation. 
The neurochemical pattern (in particular, elevated ra­
tios of DOPA/DHPG and DOPAC/DHPG) provides 
an excellent biochemical marker for this condition 
(Kaler et al., 1993Z?). Thus, analyses of plasma levels 
of catechols can diagnose or exclude Menkes disease 
in at-risk infants during the newborn period, when clin­
ical signs are extremely subtle (Gunn et al., 1984) 
and other biochemical markers unreliable (Kaler et al., 
1993a; Kaler, 1994). The abnormal pattern can also 
be detected in umbilical cord blood of affected patients, 
indicating DBH deficiency in utero and suggesting that 
analysis of catechol levels in cord blood may constitute 
a rapid, noninvasive test for Menkes disease in at-risk 
newborns (Kaler et al., 1993a, 1996).
Early treatment with parenteral copper improves the 
clinical outcome in some patients with Menkes disease 
(Kaler et al., 1996; Turner et al., 1996). The success 
of such therapy, however, appears to depend on the 
particular gene mutation (Kaler et al., 1995, 1996; 
Kaler, 1996). Further analyses of clinical, biochemi­
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cal, and molecular features should clarify the relative 
importance of mutation type and other factors in de­
termining the likelihood of response to treatment, and 
improved understanding of the copper transport pro­
cess mediated by the gene product and its homologues 
may facilitate development of novel therapies for this 
disorder. Correction of the abnormal neurochemical 
pattern could predict treatment efficacy.
Familial dysautonomia
Familial dysautonomia, inherited as an autosomal 
recessive trait, produces a constellation of clinical 
findings that suggest deficient activities of multiple 
peripheral neurotransmitter systems, including cate- 
cholaminergic systems. Affected patients have neuro­
genic orthostatic hypotension, absent lingual papillae, 
no histamine-induced flare or overflow tears, and epi­
sodic paroxysmal hypertension, nausea, and vomiting. 
All familial dysautonomia patients identified to date 
have shared an Ashkenazic Jewish background, sug­
gesting that one or a few mutations account for the 
majority of cases. The responsible gene has not yet 
been reported but has been localized to chromosome 
9q35 (Blumenfeld et ah, 1993), a region close to the 
map location of the DBH gene (9q34).
Familial dysautonomia patients have high rates of 
excretion of HVA and low rates of excretion of VMA 
(Smith et al., 1963). Although this pattern might sug­
gest deficient DBH activity, most of the patients have 
normal plasma DA and DOPAC levels. Familial dys­
autonomia patients have high plasma DOPA/DHPG 
ratios (although less elevated than in Menkes disease 
patients), a failure to increase plasma NE levels during 
orthostasis [analogous to patients with acquired dysau- 
tonomias (Ziegler et aL, 1976, 1977)], and low plasma 
EPI levels (Axelrod et al., 1996).
The plasma neurochemical pattern in familial dysau­
tonomia does not appear to fit any single abnormality 
of catecholamine synthesis, storage, reuptake, or me­
tabolism. Instead, the findings suggest more global ar­
rested differentiation of peripheral catecholamine sys­
tems during embryological development. Studies of 
nerve growth factor and its receptors have not been 
rewarding so far (Breakefield et al., 1984; Slaugen- 
haupt et al., 1995). The phenotypic pattern, neverthe­
less, points to deficient innervation of the adrenal me­
dulla and other organs. Mechanisms by which the 
bound nerve growth factor receptor signals the cell 
bodies remain poorly understood; from the neurochem­
ical phenotype, one may speculate that the genetic ab­
normality involves a protein participating in these 
mechanisms. The DBH locus should be formally ex­
cluded .
GENETIC DISEASES WITH SPECIFIC 
CATECHOLAMINERGIC PHENOTYPES: 
METABOLISM
Whereas catecholamine biosynthesis occurs mainly, 
if not exclusively, by a single pathway (tyrosine hy-
droxylation), catecholamine inactivation occurs by 
several alternative pathways that include at least three 
different intracellular enzymes (Fig. 1). From this, 
and from the absolute requirement of BH4 for tyrosine 
hydroxylation, one might predict that, compared with 
the potentially devastating effect of mutations either 
in the TH gene itself or in genes encoding enzymes 
participating in synthesis or recycling of BH4, defects 
in genes encoding catecholamine-metabolizing en­
zymes would have less serious clinical consequences.
Mutations in genes that encode membrane catechol­
amine transporters or vesicular amine transporters 
(VATs) have not been reported, despite cloning of the 
genes and identification of their chromosomal loca­
tions (Table 2). A recent report described successful 
generation of mice with a knockout of the membrane 
DA transporter (Giros et al., 1996). The animals had 
hyperlocomotion, decreased food intake, abnormal ma­
ternal behavior, and an increased likelihood of prema­
ture death. Neurochemically, the animals had de­
creased electrical stimulus-induced DA release and 
decreased tyrosine hydroxylation in dopaminergic neu­
rons. To our knowledge, no report to date has reported 
knockout or transgenic animals for the membrane NE 
transporter or for a VAT.
Monoamine oxidase (MAO) deficiency
MAO (EC 1.4.3.4) isoenzymes inactivate catechol­
amines and their 0-methylated metabolites (Fig. 1) 
and also deaminate other biogenic amines, such as se­
rotonin. The genes encoding the two subtypes of MAO 
(MAO-A and MAO-B) lie adjacent to each other on 
the X chromosome. Oxidative deamination of seroto­
nin depends on MAO-A; in vitro, both subtypes deami­
nate DOPA, DA, and NE.
Several inherited disorders involving MAO defi­
ciency have been described. A kindred of Dutch men 
with impulsivity, aggressiveness, and antisocial behav­
ior had isolated deficiency of MAO-A (Brunner et al., 
1993/;), with a point mutation in exon 8 of the MAO- 
A gene (Brunner et al., 1993a). The patients had in­
creased urinary excretion of NMN, HVA, and VMA.
Patients with Norrie disease, inherited as an X- 
linked recessive trait, have blindness, deafness, and 
variable mental retardation. The Norrie disease gene 
is contiguous with the two MAO loci at Xpll.4-pl 1.3 
(3,094, 3,075), the order from centromere to telomere 
being Norrie disease/MAO-B/MAO-A. Norrie disease 
patients can have deletions that include the Norrie dis­
ease locus and either the MAO-B locus or both MAO 
loci (Lenders et al., 1996). Two brothers with Norrie 
disease and selective MAO-B deficiency had minimal 
neurochemical alterations and no behavioral or psycho­
motor abnormalities. In contrast, a patient with deletion 
of all three loci had markedly increased levels of 0 - 
methylated amine metabolites and low levels of deami- 
nated catecholamines, with severe mental deficiency, 
autistic-like behavior, atonic seizures, and altered pe­
ripheral autonomic function (Collins et al., 1992).
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Inactivating genes
Protein Location Comments
PH 12q-24.1 BH4 cofactor; phenylketonuria
GTP-cyclohydrolase I 14q21-q22 L-DOPA-responsive dystonia
DHPR 4pl5.31 Atypical phenylketonuria
Carbinolamine dehydratase 10q22 Mild phenylketonuria
TH 11 (short arm) Fe enzyme; BH4 cofactor
Tyrosinase 1 1 q 14-q21 Cu enzyme; albinism
LAAAD 7pl3-pl1 Pyridoxine cofactor; neonatal seizures, hypotonia
Copper ATPase Xql3 Menkes disease
DBH 9q34 Cu enzyme; ascorbate cofactor; orthostatic hypotension
PNMT 17
MAO-A Xp 11.23 Impulsivity, aggressive behavior
MAO-B Xpll.4 Norrie disease (contiguous gene syndrome)
COMT 22ql 1.1-11.2
PST 16pl 1.2
NE transporter 16ql2.2 Na+-dependent
DA transporter 5pl5.3 Na+-dependent
VAT-1 (adrenal) 8p21.3
VAT-2 (brain) 10q25
AR ')
AD Iq32-q42, 3pl2, 7q31-q35 
9q22
11 p 14-p 15 
13ql4-q21
PH, phenylalanine hydroxylase; VAT, vesicular amine transporter. For other abbreviations, see legend to Fig. I.
These findings imply that MAO-A deficiency produces 
far more serious clinical consequences than does 
MAO-B deficiency. Some of these differences could 
depend on the importance of MAO-A in serotonin me­
tabolism, because mice exposed to MAO inhibitors in 
utero have increased aggressive behavior (Cases et al,
1995) mitigated by blockade of serotonin synthesis.
Pseudopheochromocytoma
Pheochromocytomas are adrenal tumors that synthe­
size and secrete catecholamines. The tumor, which 
usually is benign, typically presents as difficult-to-con- 
trol hypertension, with paroxysms of severe high blood 
pressure, tachycardia, pallor, sweating, and headache. 
Because the tumor constitutes a rare, but curable, form 
of hypertension, hypertensive patients with these 
symptoms or signs often undergo diagnostic testing for 
pheochromocytoma. Kuchel and co-workers described 
a syndrome termed “pseudopheochromocytoma” 
(Kuchel et al., 1981 ), in which the patients have clini­
cal findings consistent with pheochromocytoma, but 
instead of harboring the tumor, the patients have de­
creased plasma levels of conjugated catecholamines. 
Because sulfconjugation figures prominently in the in­
activation of circulating catecholamines [especially 
DA (Kuchel et aL, 1978; Ratge et al., 1991)], these 
patients might have a deficiency of phenolsulfotransf- 
erase (PST; EC 2.8.2.1). Plasma levels of DA sulfate 
vary widely across individuals and species (Toth et 
al., 1986; Dousa and Tyce, 1988), consistent with 
polymorphisms in the PST gene ( Aksoy and Weinshil-
boum, 1995). Patients with complete deficiency of 
PST have not been described to date; the gene encoding 
PST was cloned recently (Aksoy et al., 1994; Aksoy 
and Weinshilboum, 1995). The location is near the 
gene responsible for Batten disease, an autosomal re­
cessive disorder of lipofuscin metabolism (Taschner 
et al., 1995).
Velo-cardio-facial syndrome and DiGeorge 
syndrome
Velo-cardio-facial syndrome includes cleft palate, 
craniofacial abnormalities, learning disorders, cardiac 
defects, and psychiatric illness in adolescence and 
adulthood. DiGeorge syndrome includes immunodefi­
ciency, facial dysmorphism, mental disorders, and car­
diac defects. Both syndromes have been associated 
with interstitial deletions of chromosome 22q 11 
(Scambler et al., 1992; Franke et al., 1994). A study 
of nine families with recurrent cardiac outflow tract 
defects found that five had transmitted deletions of 
chromosome 22qll (Wilson et al., 1992). Chromo­
some 22q ll includes the locus of the gene encoding 
catechol-O-methyltransferase (COMT; EC 2.1.1.6). 
Thus, one may hypothesize that some patients with the 
velo-cardio-facial or DiGeorge syndrome may have 
only one functional COMT allele and decreased 
COMT activity (Dunham et al., 1992). Abnormal ra­
tios of O-methylated to deaminated metabolites of cat­
echolamines in plasma or urine could detect this. The 
relationship between COMT activity and clinical fea­
tures of either syndrome remains unknown.
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von Hippel-Lindau disease and 
pheochromocytoma
von Hippel-Lindau disease is an autosomal domi­
nant disorder featuring hemangioblastomas, cystic tu­
mors, renal cell carcinomas, pancreatic cysts and tu­
mors, epididymal cystadenomas, and pheochromocy- 
tomas (Choyke et al., 1995). von Hippel-Lindau dis­
ease patients with pheochromocytoma can have false 
negative results of screening tests based on plasma 
levels or urinary excretion of catecholamines or cate­
cholamine metabolites, and measurement of plasma- 
free (unconjugated) NMN and MN appears to provide 
a more sensitive biochemical marker (Lenders et al.,
1995). The von Hippel-Lindau disease gene, located 
on chromosome 3 (3p25), encodes a tumor supressor 
gene (Latif et al., 1993; Herman et al., 1994; Linehan 
et al., 1995). Many mutations at different loci in this 
gene have been documented in individuals with the 
classic von Hippel-Lindau disease phenotype; how­
ever, familial pheochromocytoma seems to be associ­
ated with mutations at a specific locus (Crossey et aL, 
1995; Gross et al., 1996; Neumann et al., 1996).
CONCLUSIONS
The wealth of knowledge regarding the synthesis 
and fate of catecholamines, the availability of sensitive 
and specific assays for l-DOPA, catecholamines, and 
most of their metabolites, and recent advances in mo­
lecular genetics afford the opportunity to glean new 
understanding of neurogenetic disorders that involve 
catecholamine metabolism. This review has presented 
several examples rather than a comprehensive picture 
of this new application of clinical neurochemistry. The 
pathways outlined in Figs. 1 and 2 suggest the exis­
tence of several other genetic defects, as yet undiscov­
ered, with predictable neurochemical and clinical con­
sequences.
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